Plus Therapeutics Initiates Part B of ReSPECT-LM Phase 1/2a Trial for Leptomeningeal Metastase (GlobeNewswire) - Sep 5, 2023 - "Plus Therapeutics, Inc...announced treatment of the first patient in Part B (Cohort 4) of the ReSPECT-LM Phase 1/2a dose escalation clinical trial of rhenium (186Re) obisbemeda for the treatment of leptomeningeal metastases (LM) from solid tumors."
Trial status • Brain Cancer • CNS Tumor • Oncology • Solid Tumor
|